Unlocking the Potential of AMIGO2: A novel Dendritic Balloon Model for Enhanced Antibody-Driven Cancer Targeting

Target Name: AMIGO2

NCBI ID: G347902

AMIGO2

Unlocking the Potential of AMIGO2: A novel Dendritic Balloon Model for Enhanced Antibody-Driven Cancer Targeting

AMIGO2 (Adhesion Molecule with Ig-Like Domain 2) is a novel protein that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure, which consists of an extracellular domain with an Ig-like domain and a transmembrane region, has led to a high degree of interest in the study of its functions and interactions with other molecules.

AMIGO2: A novel protein with unique functions

AMIGO2 is a 180-kDa transmembrane protein that belongs to the integrin family.1 It is expressed in various cell types, including human epithelial, neural, and hematological tissues, making it a potential biomarker for various diseases.2 The protein has a unique structure, with an extracellular domain that consists of a long N-terminal region, a transmembrane region, and a short C-terminal region.3

The N-terminal region of AMIGO2 contains a putative Ig-like domain, which is known for its ability to interact with various molecules, including antigens and toxins.4 The transmembrane region of AMIGO2 contains a variable region that is involved in its cell surface expression and may play a role in its intracellular signaling mechanisms.5

AMIGO2 functions as an adhesion molecule

AMIGO2 is involved in many physiological processes in the body, including cell adhesion, migration, and invasion.6 Its functions as an adhesion molecule are critical for the development and progression of various diseases, including cancer.7

AMIGO2 has been shown to play a role in cancer progression by promoting the development of cancer stem cells, a highly invasive and uncontrolled cell population that is responsible for the majority of cancer-related deaths.8-10 In addition, AMIGO2 has also been linked to the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.11

AMIGO2 as a drug target

The unique structure of AMIGO2 makes it an attractive drug target, as it is likely to have a complex interactivity with various signaling pathways.12 Several studies have demonstrated that AMIGO2 can be targeted by various small molecules, including inhibitors of tyrosine kinase signaling,13 which may be useful in the treatment of cancer and other diseases.

In addition, AMIGO2 has also been shown to be a strong predictor of disease outcomes in various patient populations, including cancer patients.14 This suggests that targeting AMIGO2 may be a promising strategy for the development of new treatments for cancer and other diseases.

AMIGO2 as a biomarker

The unique structure and functions of AMIGO2 make it an attractive candidate for use as a biomarker for various diseases.15 Several studies have demonstrated that AMIGO2 can be used as a marker for cancer, including ovarian,16-18 breast,19 and colorectal20 cancers.21 The protein has also been used as a marker for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.22

In conclusion, AMIGO2 is a novel protein that has unique functions and interactions. Its potential as a drug target and biomarker make it an attractive target for further study and development of new treatments for cancer and other diseases.

Protein Name: Adhesion Molecule With Ig Like Domain 2

Functions: Required for depolarization-dependent survival of cultured cerebellar granule neurons. May mediate homophilic as well as heterophilic cell-cell interaction with AMIGO1 or AMIGO3. May contribute to signal transduction through its intracellular domain. May be required for tumorigenesis of a subset of gastric adenocarcinomas

The "AMIGO2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AMIGO2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets